December 2, 2017
AbbVie axes late-stage study of atrasentan
© Reuters. AbbVie axes late-stage study of atrasentan
- Citing the lack of enough events to validate the primary endpoint, AbbVie (NYSE:ABBV) stops the Phase 3 SONAR study assessing atrasentan in patients type 2 diabetes and stage 2 – 4 chronic kidney disease.
- Atrasentan (ABT-627) is an endothelin A antagonist. Endothelins are peptides that constrict blood vessels and raise blood pressure.
- Previously: AbbVie (ABBV -1%) says it’s initiated a Phase 3 clinical study of diabetic nephropathy with… (May 20, 2013)
- Now read: ‘Safer’ Dividend Aristocrats Top Stock Is Leggett For Gains, And AT&T (NYSE:T) For Yield To November 2018